|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Supplementary Table 2: Observed complications from 4 to 12 months post-surgery with regards to the affected organsystem. | | | | |
| **Complication** | **Overall**  **na**  **(%1; %2)** | **NMIBC**  **na**  **(%1; %2)** | **MIBC**  **na**  **(%1; %2)** | **P-Value** |
| **Follow-up information** |  |  |  |  |
| Complete follow-up | 230 (44.1) | 59 (48) | 171 (43) |  |
| Not available | 291 (55.9) | 64 (52) | 227 (57) |  |
| **Complication y/n, na (%)** | 95  (41.3; 18.2) | 24  (40.7; 19.5) | 71  (41.5; 17.8) | 0.910 |
| **Urogenital complications, na (%)** | 28  (12.2; 5.4) | 5  (8.5; 4.1) | 23  (13.5; 5.8) | 0.314 |
| **Infectious complications, na (%)** | 41  (17,8; 7.9) | 8  (13.6; 6.5) | 33  (19.3; 8.3) | 0.321 |
| **Metabolic complications** | 16  (7; 3.1) | 5  (8.5; 4.1) | 11  (6.4; 2.8) | 0.564 |
| **Complications affecting the urinary diversion** | 23  (10; 4.4) | 6  (10.2; 4.9) | 17  (9.9; 4.3) | 0.960 |
| **Surgical complications** | 27  (11.7; 5.2) | 8  (13.6; 6.5) | 19  (11.1; 4.8) | 0.614 |
| **Highest complication according to CDC** |  |  |  | 0.338 |
| CDC grade I, na (%) | 15  (6.5; 2.9) | 5  (8.5; 4.1) | 10  (5.8; 2.5) |  |
| CDC grade II, na (%) | 47  (20.4; 8.8) | 12  (20.3; 9.8) | 35  (20.5; 8.5) |  |
| CDC grade IIIa, na (%) | 2  (0.8; 0.4) | 1  (1.7; 0.8) | 1  (0.6; 0.3) |  |
| CDC grade IIIb, na (%) | 31  (13.5; 6) | 6  (10.2; 4.8) | 25  (14.6; 6.3) |  |
| CDC grade IVa, na (%) | 0  (0; 0) | 0  (0; 0) | 0  (0; 0) |  |
| CDC grade IVb, na (%) | 0  (0; 0) | 0  (0; 0) | 0  (0; 0) |  |
| CDC grade V, na (%) | 0  (0; 0) | 0  (0; 0) | 0  (0; 0) |  |
| **Total number of complications (n/patient), median (IQR)** | 1 (1-2) | 1 (1-2) | 1 (1-2) | 0.681 |
| **Revision surgery** |  |  |  |  |
| Revision surgery y/n, na (%) | 32  (13.9; 6.1) | 7  (11.9; 5.7) | 25  (14.6; 6.3) | 0.598 |
| Amount (n/patient), median (IQR) | 2 (1-3) | 1 (1-3) | 2 (1-4) | 0.282 |
| Ureterocystoneostomy, na (%) | 4  (1.7; 0.8) | 2  (3.4; 1.6) | 2  (1.2; 0.5) | 0.272 |
| Hernia / Ileus / Lymphocele / Fistula, na (%) | 14  (6.1; 2.7) | 5  (8.5; 4.1) | 9  (5.3; 2.3) | 0.358 |
| Incision urethra / bladder neck, na (%) | 1  (0.4; 0.2) | 0  (0; 0) | 1  (0.6; 0.3) | 1.000 |
| Urinary diversion, na (%) | 3  (1.3; 0.6) | 0  (0; 0) | 3  (1.8; 0.8) | 0.572 |
| Nephrostomy / ureteral stent, na (%) | 16  (7; 3.1) | 2  (3.4; 1.6) | 14  (8.2; 3.5) | 0.372 |
| \* Indicates statistical significance. | | | | |
| a Numbers reflect the number of patients. | | | | |
| 1 Numbers reflect percentages with regards to patients with full follow-up. | | | | |
| 2 Numbers reflect percentages with regards to the overall population. | | | | |
| NMIBC = non-muscle-invasive Bladder Cancer, MIBC = muscle-invasive Bladder Cancer, IQR = Interquartile Range, CDC = Clavien-Dindo-Classification. | | | | |